Abstract: OBJECTIVE To assess the efficacy and safety of shensongyangxin capsules (SSYX) combined with amiodarone for treating paroxysmal atrial fibrillation (PAF) by using network meta-analysis. METHODS The following databases were searched up to May 2016, including PubMed, CBM, CNKI, VIP and Wanfang databases. After two reviewers independently extracted data, network meta-analysis was performed according to methods of Cochrane Collaboration. RESULTS Twenty-nine randomized controlled trials with 2 726 patients were included. Network meta-analysis showed that SSYX plus amiodarone was more effective compared with amiodarone, beta blocker, SSYX, routine treatment alone (P<0.05). However, there was no statistical difference between SSYX plus amiodarone and propafenone, SSYX plus propafenone, and SSYX plus beta blocker. When compared with control group, SSYX had no increase in the rate of adverse events. In addition, ranking results indicated that SSYX plus amiodarone was the first choice (55%). CONCLUSION Available evidence could support the combination treatment of SSYX and amiodarone for PAF patients in clinic.